TH62586A - Peptides for the treatment of cancer involving human papilloma virus (HPV) and other epithelial tissue tumors. - Google Patents

Abstract

DC60 (29/01/56) This invention relates to the field of molecular pharmacodynamics and, in particular, to the creation of peptides that are useful for the treatment of epithelial tumors, and primarily those related to ongogenic HPVs. The primary objective of this invention is to identify peptides whose structure blocks the phosphorylation domain of casein kinase II (CKII) by directly interacting with these sites. In this invention, eleven ring peptides with distinct amino acid sequences that inhibit CKII phosphorylation in vitro exhibit cytotoxicity on cells transformed with HPV-16 (CaSki) and also increase the sensitivity of these cells to the cell-stopping effect of interferon (IFN). Furthermore, this invention involves the use of these peptides conjugated or fused with other peptides and chemical compounds that penetrate cells, as well as the use of both peptides and chemical replicates. This invention relates to the field of molecular pharmacodynamics and, in particular, to the creation of... Peptides that are potentially useful for the treatment of epithelial tumors and those associated with organogenic HPVs. The primary objective of this invention is to identify peptides whose structure blocks the phosphorylation domain of casein kinase II (CKII) by directly interacting with these sites. In this invention, eleven ring peptides with distinct amino acid sequences that inhibit CKII phosphorylation in vitro exhibit cytotoxicity on HPV-16 (CaSki)-transformed cells are demonstrated, and also increase the sensitivity of these cells to the static effect of interferon (IFN). Furthermore, this invention involves the use of these peptides conjugated or fused with other peptides and chemical compounds that penetrate cells, as well as the use of both polypeptides and chemically replicated molecules.

Claims (1)

Revised 08/03/2017 11. Any peptide under claims 8-10, which includes an additional cytokine for use in the production of therapeutic drugs. 12. A peptide under claim 11, where the cytokine is IFN. 13. Any peptide under claims 8-10, for use in the production of therapeutic drugs for patients resistant to HPV treatment with IFN. 14. A vector for the expression of mammalian traits containing coding nucleic acids. For peptides identified in any of the preceding claims: 15. Peptide according to claim 4 where the fusion peptide is incorporated with a cell-penetrating peptide. 16. Peptide according to claim 15 where the cell-penetrating peptide is the HIV-1 Tat-1 protein. ----------------------- 1. Peptide for inhibition of casein kinase II (CKII) phosphorylation site, where the peptide is one of the following: a CSVRQGPVQKC; b CSSCQNSPALC; c CQIPQRTATRC; d CAKQRTDPGYC; e CWMSPRHLGTC; f CRNCTVIQFSC; g CHYLAGTVQGC; h CPLVSLRDHSC; i CKQSYLHHLLC; j CFQPLTPLCRC; or k CQSYHELLLQS 2. Peptide according to claim 1. This shows a cyclic structure. 3. A peptide under claim 1 or 2, contained in a fused polypeptide. 4. A pharmaceutical mixture comprising one peptide or a different peptide under claim 1-3, as well as a suitable vector. 5. A pharmaceutical mixture under claim 4, which, by addition, contains a cytokine. 6. A pharmaceutical mixture under claim 5, whose cytokine is interferon (IFN). 7. The use of any peptide under claim 1-3 for the inhibition of tumor cell proliferation. 8. The use under claim 7 for the treatment of both HPV-associated and non-HPV-associated tumors. 9. The use of the peptide for the treatment of premeditated HPV-associated lesions. 10. The use under claim 7-9, which uses a peptide... 11. A use under claim 10 where the cytokine is IFN. 12. Any one of claims 7-9 using the peptide to treat HPV-resistant patients with IFN therapy. 13. A vector for the expression of mammalian traits containing a DNA sequence encoding any peptide shown in any one of claims 1-3.